Kriya Appoints Scientific Co-Founder J. Fraser Wright, Ph.D., as Chief Gene Therapy Officer

UF startup Kriya Therapeutics, Inc., a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, announced the appointment of J. Fraser Wright, Ph.D., to the position of chief gene therapy officer.

Dr. Wright is a scientific co-founder of Kriya and has served as a senior advisor to the company since its founding in 2019. During his career he has contributed to numerous gene therapy development programs, including those leading to the regulatory approvals of multiple FDA-approved commercial products: Luxturna^® for RPE65^-/- Leber congenital amarosis Type 2, the first gene therapy for a genetic disease; Kymriah^®, the first CAR T-cell therapy for lymphoma and leukemia indications; and Beqvez™ for the treatment of hemophilia B.

Most recently, Dr. Wright was a professor of pediatrics at the Stanford University School of Medicine and director of technology innovation at Stanford’s Center for Definitive and Curative Medicine. His research aimed to advance the design, characterization, and production of AAV-based medicines for rare and common diseases, including addressing key immunological barriers to the successful translation of AAV gene therapies.

Read more about Kriya Appoints Scientific Co-Founder J. Fraser Wright, Ph.D., as Chief Gene Therapy Officer.